Effectiveness and Safety of PD-1 Inhibitor Rechallenge After Prior Immunotherapy in Patients Aged ≥ 60 Years with Advanced Non-Small-Cell Lung Cancer: A Single-Center Retrospective Study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Efficacy and Safety of Reinitiating PD-1 Inhibitors Following Previous Immunotherapy in Older Adults (≥ 60 Years) with Advanced Non-Small-Cell Lung Cancer: A Retrospective Analysis from a Single Center

  • By

  • Xiao-Yue Jiang

  • Xin Li

  • Hui Huang

  • Min Pan

  • Qiu-Qiu Chen

  • Chun-Qiao Chen

  • August 29, 2026

Share

  • 1

    In older patients with advanced non-small-cell lung cancer, PD-1 inhibitor rechallenge yielded a 21.4% objective response rate.

  • 2

    The median overall survival for older patients reinitiating PD-1 inhibitors was 11.3 months.

  • 3

    Safety profiles in older patients aligned with known PD-1 inhibitor toxicities, necessitating close monitoring for pneumonitis and hepatic enzyme elevations.

  • 4

    Exploratory analyses indicated improved overall survival associated with better ECOG performance status and reduced metastatic burden.

  • 5

    Older adults with NSCLC often present unique clinical characteristics, highlighting the need for tailored treatment approaches.

Original Source(s)

Effectiveness and Safety of PD-1 Inhibitor Rechallenge After Prior Immunotherapy in Patients Aged ≥ 60 Years with Advanced Non-Small-Cell Lung Cancer: A Single-Center Retrospective Study

  • by Xiao-Yue Jiang, Xin Li, Hui Huang, Min Pan, Qiu-Qiu Chen, Chun-Qiao Chen

  • August 29, 2026

Related Content

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

  • by

  • August 26, 2026

  • 5 min